This pipeline uses various statistical tests to identify mRNAs whose log2 expression levels correlated to selected clinical features.
Testing the association between 17814 genes and 9 clinical features across 72 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 4 clinical features related to at least one genes.
-
2 genes correlated to 'AGE'.
-
COL18A1 , C5ORF35
-
2 genes correlated to 'NEOPLASM.DISEASESTAGE'.
-
NOP5/NOP58 , GNL3L
-
4 genes correlated to 'PATHOLOGY.T.STAGE'.
-
TRIM11 , LOC201725 , TARS2 , ZNF652
-
4 genes correlated to 'GENDER'.
-
CYORF15A , JARID1D , CYORF15B , UCHL5IP
-
No genes correlated to 'Time to Death', 'PATHOLOGY.N.STAGE', 'PATHOLOGY.M.STAGE', 'RACE', and 'ETHNICITY'.
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=0 | ||||
AGE | Spearman correlation test | N=2 | older | N=1 | younger | N=1 |
NEOPLASM DISEASESTAGE | Kruskal-Wallis test | N=2 | ||||
PATHOLOGY T STAGE | Spearman correlation test | N=4 | higher stage | N=3 | lower stage | N=1 |
PATHOLOGY N STAGE | Wilcoxon test | N=0 | ||||
PATHOLOGY M STAGE | Wilcoxon test | N=0 | ||||
GENDER | Wilcoxon test | N=4 | male | N=4 | female | N=0 |
RACE | Kruskal-Wallis test | N=0 | ||||
ETHNICITY | Wilcoxon test | N=0 |
Time to Death | Duration (Months) | 0.5-101.1 (median=36.6) |
censored | N = 58 | |
death | N = 14 | |
Significant markers | N = 0 |
AGE | Mean (SD) | 60.54 (12) |
Significant markers | N = 2 | |
pos. correlated | 1 | |
neg. correlated | 1 |
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE I | 40 | |
STAGE II | 13 | |
STAGE III | 14 | |
STAGE IV | 5 | |
Significant markers | N = 2 |
ANOVA_P | Q | |
---|---|---|
NOP5/NOP58 | 9.01e-06 | 0.161 |
GNL3L | 1.626e-05 | 0.29 |
PATHOLOGY.T.STAGE | Mean (SD) | 1.67 (0.84) |
N | ||
1 | 41 | |
2 | 14 | |
3 | 17 | |
Significant markers | N = 4 | |
pos. correlated | 3 | |
neg. correlated | 1 |
PATHOLOGY.N.STAGE | Labels | N |
class0 | 35 | |
class1 | 3 | |
Significant markers | N = 0 |
PATHOLOGY.M.STAGE | Labels | N |
M0 | 67 | |
M1 | 5 | |
Significant markers | N = 0 |
GENDER | Labels | N |
FEMALE | 29 | |
MALE | 43 | |
Significant markers | N = 4 | |
Higher in MALE | 4 | |
Higher in FEMALE | 0 |
RACE | Labels | N |
ASIAN | 1 | |
BLACK OR AFRICAN AMERICAN | 5 | |
WHITE | 62 | |
Significant markers | N = 0 |
-
Expresson data file = KIRC-TP.medianexp.txt
-
Clinical data file = KIRC-TP.merged_data.txt
-
Number of patients = 72
-
Number of genes = 17814
-
Number of clinical features = 9
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.